Postoperative atrial fibrillation (POAF) is a serious yet common complication, also a known predictor of in-hospital morbidity and short-term survival after coronary artery bypass grafting (CABG) surgery, occurring in 25% to 40% of patients[@b1][@b2][@b3][@b4][@b5]. Although POAF after on-pump CABG is benign and self-limiting in most cases, in some cases, it can cause stroke or congestive heart failure and may lead to prolonged hospital stay, increased cost, additional concomitant treatment, and worsened prognosis[@b6]. Some risk factors and possible preventive strategies for POAF have been identified, like echocardiographic parameters, age, number of vessels bypassed, vessel location, net fluid balance on the operative day, POAF score and so on[@b7][@b8][@b9][@b10]. However, little is known about the molecular basis of POAF susceptibility.

Identification of patients who are at higher risk of POAF using genetic markers might be an important step for prevention of this type of operative complication and may provide important insight into the pathogenesis of AF and new therapeutic strategies for individual patients according to relative risk. Druing last 20 years, researchers have evaluated multiple genetic susceptibility loci for POAF susceptibility after CABG, although some studies are under-powered[@b11][@b12][@b13][@b14][@b15][@b16]. However, all of these studies have been conducted among people of European ancestry. Considering that race was a surrogate for genetic determinants of POAF susceptibility after CABG due to genetic disparities among racial/ethnic groups[@b17][@b18], investigation of previously reported loci in non-European populations may help to evaluate the generalizability of these initial findings and to identify causal variants. Thus, we conducted this study to evaluated the previous positive findings for POAF susceptibility after CABG among Chinese population.

Materials and Methods
=====================

Subjects
--------

The methods were carried out in "accordance" with the approved guidelines. Patients undergoing primary CABG surgery without planned concurrent valve surgery were enrolled. The exclusion criteria were as follows: prior cardiac surgery; emergency surgical procedure; acute coronary syndrome; prior myocardial infarction; congestive heart failure; significant valvular heart disease; prior implantation of a permanent pacemaker, implantable cardioverter defibrillator, or cardiac resynchronization therapy defibrillator converted to a standard on-pump procedure; and use of class I or class III anti-arrhythmic agents. Also, the patients were excluded if they were not in sinus rhythm during echocardiography. In current study, we first conducted a case-cohort study in 1,348 subsequently patients from the total cohort as the discovering stage. Then, 2,000 individuals of the remaining cohort comprised the replication cohort for our study. Study protocols were approved by respective institutional review boards of Laiwu People's Hospital, and participants were enrolled after informed written consent was obtained.

Data collection and end-point definition
----------------------------------------

An uniform questionnaire was used to collect patient demographics, preoperative and procedural factors, perioperative medication use, postoperative outcomes obtained from patient interview and medical records, and staff interviews. Diagnosis of new onset POAF was based on postoperative electrocardiogram or rhythm strip or documented by at least 2 of the following: progress notes, nursing notes, discharge summary, or change in medication[@b3]. Trained medical record data abstractors reviewed the medical records of all subjects. To avoid investigators-related biases, all the physicians involved in patients' care were blinded to the results of the genetic and biochemical analyses. The in-hospital clinical course of all patients, including major and minor postoperative complications were prospectively recorded.

SNP selection and genotyping
----------------------------

Through a comprehensive retrieval of Pubmed for previous positive findings for POAF susceptibility after CABG, we identified nine independent loci, including four loci in GRK5 gene (rs3740563, rs4752292, rs11198893, and rs10787959), 3 in 4q25 region (rs2200733, rs13143308, rs10033464), 1 in IL6 gene (rs1800795), and 1 in HSP70 gene (rs2227956). All of the nine SNP, which were not in linkage disequilibrium (LD), were evaluated in the discovering stage. DNA was extracted from white blood cells using standard procedures. Genotyping was performed using validated TaqMan assays (Applied Biosystems). PCR product was amplified utilizing 0.9 μM each of the forward primer and reverse primers, 0.2 μM each of the FAM and VIC MGB (minor groove binder) sequence-specific probes, 3 ng DNA, 5.0 mM MgCl~2~, and 1X TaqMan Universal PCR Master Mix containing AmpliTaq Gold DNA Polymerase in a 5.5 μl reaction volume. Both the SNPs had a call rate of greater than 99%. QC concordance for samples was 100%.

Statistical Analyses
--------------------

All statistical tests were 2-sided and a *P* value significance threshold of 0.05 was set. All analyses were conducted using SAS, version 9.2 (SAS Institute, Cary, North Carolina). Descriptive statistics of clinical variables are presented as frequency and percentage for categorical variables and mean ± SD or median (interquartile range) for continuous variables.

Hardy--Weinberg equilibrium (HWE) was tested by comparing observed and expected genotype frequencies among controls (x^2^ test). For each of the SNPs, allelic associations with POAF were assessed using logistic regression analyses adjusted for the POAF Risk Index. The same logistic regression model adjusted for the POAF Risk Index was applied in the replication dataset. To assess the overall effect of candidate SNPs, we then conducted a meta-analysis using the weighted Z-score meta-analysis as implemented in METAL (<http://www.sph.umich.edu/csg/abecasis/metal>).

Results
=======

Characteristics of the discovery and validation cohorts, stratified by the occurrence of POAF, are shown in [Table 1](#t1){ref-type="table"}. The mean age of the discovery cohort was 68.0 ± 9.8 years; 287 (21.3%) of the subjects were female. Of the 1,348 patients in this cohort, 405 (30.0%) developed POAF. For the validation cohort, the mean age was 67.2 ± 9.8 years with 22.1% being female, and 630 (31.5%) of the total subject developed POAF. People in the two genotyping stages were generally comparable for BMI, medical history of hypertension, diabetes, COPD, hyperlipidemia, hemodialysis, and preoperative medications of ACEI/ARB, calcium channel blocker, β-blocker, statins, and postoperative medications of HMG-CoA reductase inhibitor and β-blocker discontinued.

A total of nine independent loci which were previously reported to be associated with POAF susceptibility after CABG were included in the current study, including four loci in GRK5 gene (rs3740563, rs4752292, rs11198893, and rs10787959), 3 in 4q25 region (rs2200733, rs13143308, rs10033464), 1 in IL6 gene (rs1800795), and 1 in HSP70 gene (rs2227956). Of these 9 markers, none was found to deviate from HWE (P \> 0.05). The estimates of effect of these variants on POAF susceptibility after CABG in discovery stage, adjusted for age and gender are shown in [Table 2](#t2){ref-type="table"}. The allelic pattern of six SNPs (GRK5 rs3740563, GRK5 rs4752292, GRK5 rs11198893, GRK5 rs10787959, 4q25 rs13143308, and 4q25 rs10033464) was differentially distributed among the the patients who developed POAF and those who didn't develop POAF, with the p-value being significant (ranged from 6.87 × 10^−6^ to 0.022). The most signigicant association was detected for GRK5 rs11198893 (P = 6.87 × 10^−6^). Each additional copy of minor allele A was associated with a 1.54-fold increased risk of developing POAF (OR = 1.54, 95% CI: 1.27--1.85).

Then, the six significant vanriants were evaluated in a validation cohort with 630 subjects with POAF and 1370 subjects without POAF ([Table 3](#t3){ref-type="table"}). Two variants in GRK5 gene (rs4752292, and rs11198893) were replicated with significance. For rs4752292, each additional copy of minor allele T was associated with a 1.32-fold increased risk of developing POAF (OR = 1.32, 95% CI: 1.15--1.50, P = 5.82 × 10^−5^). While for rs11198893, each additional copy of minor allele A was associated with a 1.47-fold increased risk of developing POAF (OR = 1.47, 95% CI: 1.28--1.69, P = 1.16 × 10^−7^). Sensitivity analyses were used to evaluated the robustness of these findings by additional adjustments by age, gerder, BMI, medical history, preoperative medications, and postoperative medications were conducted respectively. The results didn't change materially.

Discussion
==========

AF is the most frequently occurring arrhythmia both in ambulatory and postcardiac surgical patients and is associated with significant morbidity. There is strong evidence for heritability of POAF. In this large population-based, two-stage, case-cohort study, we idenfied that GRK5 rs4752292, and GRK5 rs11198893 were significantly associated with increased risk of POAF after CABG. Testing for these genetic markers could improve risk stratification and potentially personalize therapy for preventing POAF. To the best of our knowledge, this study is the first to demonstrate that genetic variations in the GRK5 gene are associated with POAF risk in patients who undergo CABG surgery in Asians.

For more than 2 decades, researchers have attempted to identify predictors of AF after cardiac surgery[@b19]. In the general population, the pathophysiology of AF has been extensively studied, yet it remains incompletely understood[@b19][@b20]. Similarly, in the context of cardiac surgery, numerous risk factors for POAF have been identified, but the pathophysiology of this entity is still to a large extent elusive[@b21][@b22][@b23][@b24]. Identification of genetic markers for POAF might be an important step for prevention of this type of operative complication and may provide important insight into the pathogenesis of AF and new therapeutic strategies for individual patients according to relative risk. Previous researchers have identified multiple genetic susceptibility loci for POAF susceptibility after CABG[@b11][@b12][@b13][@b14][@b15][@b16], although all of these studies have been conducted among people of European ancestry. In 2003, Gaudino *et al.*[@b11] first identified that The −174G/C interleukin-6 polymorphism could influence postoperative interleukin-6 levels and POAF in 110 primary isolated coronary artery bypass patients, which are strong arguments in favor of an inflammatory component of the development of atrial arrhythmias after cardiac surgery. Then many studies evaluated other genetic determinants of POAF[@b11][@b12][@b13][@b14][@b15][@b16]. These data open new perspectives on a possible genetic determinants of POAF after CABG and suggest a genetic modulation of the postoperative course and outcome after cardiac surgery.

In current study, we first identified genetic variations in the GRK5 gene is associated with POAF risk after CABG in Asians. G protein-coupledreceptor kinase 5 (GRK5), which encodes a member of the guanine nucleotide-binding protein (G protein)-coupled receptor kinase subfamily of the Ser/Thr protein kinase family, was located in chromosome 10q26.11[@b25]. Phosphorylation of ARRB1 by GRK5 inhibits G-protein independent MAPK1/MAPK3 signaling downstream of 5HT4-receptors and GRK5 potentially acts as a physiological regulator of ű-adrenergic receptor activity[@b26][@b27]. GRK5 is abundantly expressed in the normal human heart and involves in many biological processes of cardiovascular system[@b28][@b29][@b30][@b31][@b32][@b33]. Liggett *et al.*[@b31] found that a functional loss-of-function SNP (rs17098707) in the coding region of the GRK5 gene has been associated with blunting the effects of ű-adrenergic receptor agonists via enhanced receptor desensitization. Furthermore, Kertai *et al.*[@b16] confirmed that genetic variation in GRK5 is associated with POAF despiteperioperative BB therapy in patients undergoing CABG surgery. All of these findings validated the importance of GRK5 gene in the developmet of POAF after CABG.

A strength of this study was the acceptable statistical power to distinguish relatively small genotype associations. Another strength of the current study was a large population, a two-stage genotyping design to minimize type I error. Limitations for this study should be more larger-scale studies are needed to warranted our findings, which may ultimately lead to a comprehensive understanding of the conceivable roles in POAF. Second, the candidate gene design might bias the real situation.

Conclusively, genetic variants in GRK5 gene are identified to be independently associated with an increased risk of POAF. These findings delineate an important genetic role in the etiology of POAF and provide a detailed genomic landscape in which to examine biological mechanisms.
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###### Demographic Characteristics of the Discovery and Validation Cohorts.

  Demographic                    Discovery Cohort   Validation Cohor                                         
  ----------------------------- ------------------ ------------------ ------- ------------- ---------------- -------
  Age, y                            68.5 ± 9.6         67.8 ± 9.9      0.230   67.4 ± 10.3     67.1 ± 9.6     0.526
  Gender (% female)                 87 (21.6%)        200 (21.2%)      0.911   143 (22.7%)    300 (21.9%)     0.689
  BMI, kg/m ^2^                     24.3 ± 4.3         24.8 ± 4.7      0.067   24.3 ± 4.3      24.5 ± 4.7     0.364
  Medical history                                                                                            
  Hypertension                     324 (80.0%)        725 (76.9%)      0.207   530 (84.1%)   1,140 (83.2.%)   0.608
  Diabetes                         104 (25.7%)        225 (23.9%)      0.476   158 (25.1%)    326 (23.8%)     0.534
  COPD                              22 (5.5%)          44 (4.7%)       0.550    37 (5.8%)      78 (5.7%)      0.873
  Hyperlipidemia                   201 (49.7%)        433 (45.9%)      0.211   290 (46.1%)    629 (45.9%)     0.960
  Hemodialysis                      53 (13.0%)        110 (11.7%)      0.463   80 (12.7%)     156 (11.4%)     0.398
  Preoperative medications                                                                                   
  ACEI/ARB                         196 (48.4%)        440 (46.7%)      0.558   299 (47.4%)    638 (46.6%)     0.711
  Calcium channel blocker           66 (16.3%)        140 (14.8%)      0.498   102 (16.2%)    216 (15.8%)     0.810
  β-blocker                        319 (78.8%)        736 (78.1%)      0.770   515 (81.7%)   1,133 (82.7%)    0.603
  Statins                           96 (23.7%)        234 (24.8%)      0.664   143 (22.7%)    326 (23.8%)     0.591
  Postoperative medications                                                                                  
  HMG-CoA reductase inhibitor      304 (75.1%)        730 (77.4%)      0.349   484 (76.8%)   1,059 (77.3%)    0.815
  β-blocker discontinued            11 (2.7%)          33 (3.5%)       0.458    22 (3.5%)      53 (3.9%)      0.681

###### Logistic Regression Analysis of Genetic Predictors of Postoperative Atrial Fibrillation in the Study Populations (Stage I).

                                               Discovery Cohort                              
  ------------ ------- ----------------- ----- ------------------ ------ ------------------- -----------------------
  rs3740563     GRK5    Chr10:121095400   C/A  0.27               0.22   1.31 (1.09--1.58)          **0.005**
  rs4752292     GRK5    Chr10:121100153   G/T  0.35               0.29   1.32 (1.11--1.57)    **1.98 × 10**^−**3**^
  rs11198893    GRK5    Chr10:121107900   G/A  0.29               0.21   1.54 (1.27--1.85)    **6.87 × 10**^−**6**^
  rs10787959    GRK5    Chr10:121131313   G/A  0.47               0.42   1.22 (1.04--1.44)          **0.016**
  rs2200733     4q25    Chr4:111929618    C/T  0.42               0.39   1.13 (0.96--1.34)            0.145
  rs13143308    4q25    Chr4:111933868    T/G  0.27               0.32   0.79 (0.65--0.94)    **9.73 × 10**^−**3**^
  rs10033464    4q25    Chr4:111940210    G/T  0.25               0.21   1.25 (1.03--1.52)          **0.022**
  rs1800795      IL6     Chr7:22727026    G/C  0.07               0.06   1.18 (0.85--1.64)            0.327
  rs2227956     HSP70    Chr6:31810495    T/C  0.21               0.19   1.13 (0.92--1.39)            0.230

^\*^Major allele/minor allele.

P value in bold means statistically significant.

###### Logistic Regression Analysis of Genetic Predictors of Postoperative Atrial Fibrillation in the Study Populations (Stage I and II).

  SNP           Gene/Loci   Alleles     Stages        OR (95% CI)                P
  ------------ ----------- --------- ------------ ------------------- -----------------------
  rs3740563       GRK5        C/A     Discovery    1.31 (1.09--1.58)           0.005
                                      Validation   1.21 (0.89--1.38)           0.089
  rs4752292       GRK5        G/T     Discovery    1.32 (1.11--1.57)   **1.98 × 10**^−**3**^
                                      Validation   1.31 (1.07--1.63)         **0.012**
                                        Total      1.32 (1.15-1.50)    **5.82 × 10**^−**5**^
  rs11198893      GRK5        G/A     Discovery    1.54 (1.27--1.85)   **6.87 × 10**^−**6**^
                                      Validation   1.38 (1.01--1.56)         **0.004**
                                        Total      1.47 (1.28--1.69)   **1.16 × 10**^−**7**^
  rs10787959      GRK5        G/A     Discovery    1.22 (1.04--1.44)           0.016
                                      Validation   0.97 (0.84-1.21)            0.744
  rs13143308      4q25        T/G     Discovery    0.79 (0.65--0.94)       9.73 × 10^−3^
                                      Validation   1.17 (0.99--1.32)           0.032
  rs10033464      4q25        G/T     Discovery    1.25 (1.03--1.52)           0.022
                                      Validation   1.05 (0.87--1.33)           0.652
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